New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novavax, Inc. (NVAX) vs Tyra Biosciences, Inc. (TYRA)

Novavax, Inc. and Tyra Biosciences, Inc. are both Biotechnology companies. Novavax, Inc. and Tyra Biosciences, Inc. are of similar size ($1.4B and $1.3B). Tyra Biosciences, Inc. has the higher net margin (0.00% vs −18.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Novavax, Inc. leads on 7 and Tyra Biosciences, Inc. on 5.

Valuation

Metric NVAX TYRA Biotechnology median
P/E n/m n/m 8.26
P/S 3.10 n/m 9.20
P/B n/m 1.97 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m n/m 0.67
EV/Sales 2.30 n/m 9.05
Earnings yield (5.95%) (13.38%) (34.24%)
Free cash flow yield (19.23%) (8.79%) (24.77%)

Profitability

Metric NVAX TYRA Biotechnology median
Gross margin 78.01% 0.00% 70.18%
Operating margin (21.23%) 0.00% 0.00%
Net margin (18.64%) 0.00% 0.00%
Free cash flow margin (59.09%) 0.00% 0.00%
Return on equity 41.08% (34.89%) (51.58%)
Return on assets (7.42%) (32.99%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVAX TYRA Biotechnology median
Revenue growth (TTM) (61.33%) — 7.20%
EPS growth (last fiscal year) 309.76% (33.11%) 29.04%
Revenue growth, 5-year CAGR 18.76% — 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVAX TYRA Biotechnology median
Debt to equity (1.35) 0.00 0.00
Current ratio 2.15 23.93 4.83
Net debt to EBITDA (1.04) 1.94 1.01

Dividend

Metric NVAX TYRA Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric NVAX TYRA Biotechnology median
Market cap 1.27b 1.36b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack